Moroz C, Kupfer B, Lindner A, Many M
Cancer Immunol Immunother. 1985;20(3):236-40. doi: 10.1007/BF00205583.
Considerable interest has been focused on the use of interferon (IFN) and IFN-inducers as antineoplastic agents in humans. The current report will focus on the effect of intravesical administration of Poly I: Poly C on NK activity in patients with TCC of the urinary bladder. NK cytotoxicity was measured in 14 patients with primary TCC, 8 patients received Poly I: Poly C and 5 other patients received intravesical thiotepa. Blood samples were obtained prior to and 48 h following each drug treatment. A variation in the initial NK level determined prior to treatment was observed in the different TCC patients: 5 patients treated with Poly I: Poly C and 5 patients treated with thiotepa exhibited low NK activity prior to treatment, whereas the other 3 patients who were treated with Poly I: Poly C had high initial NK levels. Following drug treatment it was shown that a significant elevation in the NK cytotoxicity was only observed in patients treated by intravesical Poly I: Poly C who had low NK activity prior to treatment. No such effect was observed in patients treated with thiotepa or in patients treated with Poly I: Poly C who exhibited a high NK activity prior to treatment.
干扰素(IFN)和IFN诱导剂作为人类抗肿瘤药物的应用已引起了广泛关注。本报告将聚焦于膀胱内灌注聚肌苷酸:聚胞苷酸(Poly I: Poly C)对膀胱移行细胞癌(TCC)患者自然杀伤(NK)活性的影响。对14例原发性TCC患者的NK细胞毒性进行了检测,其中8例患者接受了Poly I: Poly C治疗,另外5例患者接受了膀胱内噻替派治疗。在每次药物治疗前及治疗后48小时采集血样。不同的TCC患者在治疗前测定的初始NK水平存在差异:5例接受Poly I: Poly C治疗的患者和5例接受噻替派治疗的患者在治疗前NK活性较低,而另外3例接受Poly I: Poly C治疗的患者初始NK水平较高。药物治疗后发现,仅在治疗前NK活性较低且接受膀胱内Poly I: Poly C治疗的患者中观察到NK细胞毒性显著升高。在接受噻替派治疗的患者或治疗前NK活性较高且接受Poly I: Poly C治疗的患者中未观察到这种效应。